NASH: Concurrent Fibrosis and Fat Imaging and Quantification
In the particular case of NAFLD and NASH, we concurrently acquire SHG (collagen) and 2PE (tissue morphometrics and inflammation) images from the same unstained FFPE section, which is returned undamaged for further molecular pathology tests if needed.
See 2017 publications on our website page here.
Our image Analysis tools concurrently quantify fibrosis and Microvesicular Steatosis: Fibrosis is quantified using the Second Harmonic Generation (SHG) channel, both in terms of Content and structure. Steatosis is quantified using the Two-Photon excitation Fluorescence (2PE) channel: we extract and quantify the microvesicular and macrovesicular features. Vascular features (also "round and dark") are excluded as they are surrounded by collagen (identified by SHG) and often contain internal 2PE fluorescent from hemoglobin.
In 2018, both Fibrosis and the NAS-activity score can potentially become fully automated. Subscribe here if you are interested to stay informed of our progress.
Concordance with conventional Histopathology
In this case Study (Fat Diet NASH Mouse model N=4, vs Drug A and Drug B candidates, N=4) we highlight the combined efficacy of the drug candidates as anti-steatotic and and-fibrotic compounds. Dots are the group averages. Our method uses ONE FFPE slide to derive all the information. Turnaround time is les than 2 weeks for a typical 4 arms x 4 animals study.
Fibrosis Morphometric Phenotyping establishes pre-clinical continuous scores to assess the severity and progression of fibrosis.
Towards a fully automated, robust and continuous scoring of Fibrosis (in NASH)
Is Fibrosis Morphometric Phenotyping a novel tool for patient classification ?
Early result support the hypothesis that there are multiple forms of fibrosis and that the related fibrosis phenotypes are very heterogeneous. The case study (below) shows that our morphometric phenotyping tools can classify pediatric patients with NASH-1 and NASH-2 forms, two well described forms of NASH. Further validation studies are on-going. We welcome investigator initiated study proposals in this field.